Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
430 stopped studies mapped to Liver Carcinoma and descendants · 93% state a reason
Over the 430 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00047333 | Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed | Phase 2 | terminated | Jan 27, 2003 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00699374 | Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer | Phase 3 | terminated | Jun 18, 2008 | Pfizer | See termination reason in detailed description. | Other (stated, no rule matched) |
| NCT01071434 | Feasibility of Using Real-time Cine-MRI for Treating Moving & Deforming Tumors | — | terminated | Feb 19, 2010 | Stanford University | PI left | Investigator |
| NCT00966251 | Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With… | Phase 1 / Phase 2 | terminated | Aug 26, 2009 | CureTech Ltd | The study was stopped because of slow accrual | Enrollment / accrual |
| NCT01009593 | Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular… | Phase 3 | terminated | Nov 6, 2009 | Abbott | See termination reason in detailed description | Other (stated, no rule matched) |
| NCT00838968 | The Efficiency of Postoperative Interferon-alpha Treatment in p48 Positive Patients With… | N/A | withdrawn | Feb 9, 2009 | Fudan University | we have found another marker (microRNA26) which is more sensitive to evaluate the effect of… | Other (stated, no rule matched) |
| NCT00426829 | Proton Therapy and Bevacizumab for Primary Liver Tumors | Phase 1 | terminated | Jan 25, 2007 | M.D. Anderson Cancer Center | Low Accural | Other (stated, no rule matched) |
| NCT00562666 | Immunotherapy of Hepatocellular Carcinoma With Gamma Delta T Cells(ICAR) | Phase 1 | terminated | Nov 22, 2007 | Rennes University Hospital | not stated | Not stated |
| NCT01327521 | Transarterial Chemoembolization vs CyberKnife for Recurrent Hepatocellular Carcinoma | Phase 3 | withdrawn | Apr 1, 2011 | Albert Koong | Accrual below target levels | Enrollment / accrual |
| NCT00618384 | TACE and Sorafenib for Advanced Hepatocellular Carcinoma (HCC)(SOCRATES) | Phase 2 | terminated | Feb 20, 2008 | Heinrich-Heine University, Duesseldorf | not stated | Not stated |
| NCT01194206 | Stereotactic Body Radiation Therapy in Liver Cancer That Cannot be Removed by Surgery or… | Phase 2 | withdrawn | Sep 2, 2010 | Case Comprehensive Cancer Center | Study being rewritten | Other (stated, no rule matched) |
| NCT01337492 | Pilot Study Sorafenib as Bridge to Orthotopic Liver Transplantation (OLT) | Early Phase 1 | terminated | Apr 19, 2011 | Case Comprehensive Cancer Center | slow accrual | Enrollment / accrual |
| NCT00151671 | Effect of a Perioperative Oral Nutritional Supplementation on Patients Undergoing Hepatic…(IMPACT) | Phase 2 / Phase 3 | terminated | Sep 9, 2005 | Rennes University Hospital | insufficient enrollment rate | Enrollment / accrual |
| NCT01318200 | Transarterial Chemoembolization (TACE) vs. CyberKnife for Recurrent Hepatocellular… | Phase 3 | withdrawn | Mar 18, 2011 | Accuray Incorporated | not stated | Not stated |
| NCT01441388 | A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid… | Phase 1 | withdrawn | Sep 27, 2011 | Pfizer | Business/Operational issues | Sponsor / business decision |
| NCT01245582 | Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced…(SECOX) | Phase 3 | withdrawn | Nov 22, 2010 | Sanofi | not stated | Not stated |
| NCT00225290 | Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver… | Phase 3 | terminated | Sep 23, 2005 | TTY Biopharm | slowly recruitment rate | Enrollment / accrual |
| NCT00568308 | Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma(PATHWAY) | Phase 3 | terminated | Dec 6, 2007 | Progen Pharmaceuticals | Commercial decision to discontinue the study | Other (stated, no rule matched) |
| NCT00470340 | Chemotherapy or Not, Following Complete Treatment of Hepatic Cancer in Cirrhotic Patients(GEMOXIAL) | Phase 3 | terminated | May 7, 2007 | Assistance Publique - Hôpitaux de Paris | during the study | Other (stated, no rule matched) |
| NCT00791544 | Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma | Phase 1 / Phase 2 | terminated | Nov 14, 2008 | Sanofi | Company decision to discontinue the AVE1642 development program, not due to any safety or efficacy… | Safety / toxicity |
| NCT00280007 | Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma | Phase 2 | terminated | Jan 20, 2006 | Medical University of Vienna | Safety concerns in the treatment arm | Safety / toxicity |
| NCT00909558 | Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on… | Phase 1 | suspended | May 28, 2009 | Envita Medical Center, Inc. | not stated | Not stated |
| NCT00319683 | A Study of ADH300004 and 5-Fluorouracil in Locally Advanced, Recurrent, or Metastatic… | Phase 1 / Phase 2 | terminated | Apr 27, 2006 | Adherex Technologies, Inc. | Lack of funds | Funding |
| NCT00165633 | A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of… | Phase 2 / Phase 3 | terminated | Sep 14, 2005 | Eisai Limited | not stated | Not stated |
| NCT00415155 | A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma | Phase 1 / Phase 2 | withdrawn | Dec 22, 2006 | Eli Lilly and Company | Trial cancelled | Other (stated, no rule matched) |
| NCT00351195 | Etoposide, Oxaliplatin and Capecitabine in Advanced Hepatocellular Carcinoma (HCC) | Phase 2 | terminated | Jul 12, 2006 | Rigshospitalet, Denmark | Did not meet the criteria for continuation to second stage | Other (stated, no rule matched) |
| NCT00440934 | A Study of Electromagnetic Waves in the Treatment of the Advanced Hepatocarcinoma(THBC002) | Phase 2 | terminated | Feb 27, 2007 | Pasche, Boris, M.D. | Poor patient accrual | Enrollment / accrual |
| NCT00355212 | Comparison Between Radiofrequency Versus Ethanol Injection for the Treatment of… | Phase 3 | terminated | Jul 21, 2006 | Azienda Ospedaliera San Giovanni Battista | not stated | Not stated |
| NCT00034333 | Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in… | Phase 2 / Phase 3 | terminated | Apr 26, 2002 | FeRx | not stated | Not stated |
| NCT00057382 | T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma… | Phase 2 / Phase 3 | terminated | Apr 2, 2003 | Tularik | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Jan 23, 2013source: clinicaltrials